Zoetis Inc. (NYSE:ZTS - Free Report) - Investment analysts at William Blair raised their FY2025 earnings per share (EPS) estimates for shares of Zoetis in a report issued on Tuesday, August 5th. William Blair analyst B. Vazquez now expects that the company will post earnings of $6.34 per share for the year, up from their prior forecast of $6.26. The consensus estimate for Zoetis' current full-year earnings is $6.07 per share. William Blair also issued estimates for Zoetis' Q2 2026 earnings at $1.87 EPS and FY2026 earnings at $6.84 EPS.
Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 57.16% and a net margin of 27.83%. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the prior year, the business earned $1.56 EPS. The firm's revenue for the quarter was up 4.2% on a year-over-year basis.
Other analysts also recently issued reports about the company. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Piper Sandler increased their price objective on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. UBS Group lowered their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $204.63.
View Our Latest Stock Report on ZTS
Zoetis Stock Up 0.3%
ZTS stock opened at $146.63 on Thursday. The stock's 50 day simple moving average is $157.52 and its 200 day simple moving average is $160.07. Zoetis has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. The company has a market cap of $65.28 billion, a P/E ratio of 25.24, a price-to-earnings-growth ratio of 2.42 and a beta of 0.88.
Zoetis Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a dividend of $0.50 per share. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. Zoetis's dividend payout ratio is currently 34.42%.
Insider Activity
In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president owned 15,129 shares in the company, valued at $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.18% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Zoetis
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Zoetis by 0.5% in the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock worth $6,842,222,000 after buying an additional 189,287 shares in the last quarter. Polen Capital Management LLC raised its position in shares of Zoetis by 17.6% in the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after buying an additional 1,313,653 shares in the last quarter. Northern Trust Corp raised its position in shares of Zoetis by 1.2% in the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock worth $1,071,032,000 after buying an additional 78,508 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Zoetis by 2.2% in the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock worth $847,293,000 after buying an additional 109,791 shares in the last quarter. Finally, Unisphere Establishment raised its position in shares of Zoetis by 7.3% in the fourth quarter. Unisphere Establishment now owns 4,800,000 shares of the company's stock worth $782,064,000 after buying an additional 325,000 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.
About Zoetis
(
Get Free Report)
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.